Beacon Therapeutics
Highly Engaged Employees
Manufacturing · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
14193 NW 119th Ter Ste 10, Alachua, Flor...Phone Number
(386) 462-2204Website
www.beacontx.comRevenue
$16.3 MillionIndustry
About Beacon Therapeutics
Beacon Therapeutics Org Chart
Is Beacon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Beacon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Beacon Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Beacon Therapeutics
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Beacon Therapeutics recently announced quarterly report
Product Launch: Get notified when Beacon Therapeutics launches new products
Click to see if Beacon Therapeutics had a recent Job posting/layoffs
Beacon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Beacon Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Beacon Therapeutics
Find 2 more new buyers
Compare Similar Companies to Beacon Therapeutics
Compare insights from companies similar to Beacon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Beacon Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Beacon Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Beacon Therapeutics.
Beacon Therapeutics financials insights
Gather financial insights about Beacon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Other Financing Round
$120M
Series B
$170M
Beacon Therapeutics Tech Stack
A closer look at the technologies used by Beacon Therapeutics
Most Recent Scoops
Beacon Therapeutics News & Media
Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting
LONDON and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced that it will deliver five presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 3-7, 2026 in Denver, Colorado.Beacon Therapeutics appoints Ryan Robinson as Chief Financial Officer
LONDON and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that Ryan Robinson has been appointed Chief Financial Officer. Ryan succeeds Tom Biancardi following the closing of an oversubscribed Series C financing announced in January 2026.Beacon Therapeutics to Participate in TD Cowen's 46th Annual Health Care Conference
LONDON and CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that Lance Baldo, M.D., Chief Executive Officer of Beacon Therapeutics and other members of the management team, will participate in TD Cowen's 46th Annual Health Care Conference being held March 2-4, 2Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million
LONDON and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that it has raised over $75 million in an oversubscribed Series C financing led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the ve
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Beacon Therapeutics
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.... Read More
